159 related articles for article (PubMed ID: 32139273)
1. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
[TBL] [Abstract][Full Text] [Related]
2. Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
Haskins CB; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Breast Cancer Res Treat; 2019 Feb; 174(1):197-208. PubMed ID: 30465157
[TBL] [Abstract][Full Text] [Related]
3. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
4. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
6. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution.
Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV
Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209
[TBL] [Abstract][Full Text] [Related]
7. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
8. The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.
Neuner JM; Fergestrom NM; Laud PW; Nattinger AB; Beyer KMM; Flynn KE; Pezzin LE
Cancer; 2019 Nov; 125(22):3960-3965. PubMed ID: 31373689
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Riley GF; Warren JL; Harlan LC; Blackwell SA
Medicare Medicaid Res Rev; 2011 Dec; 1(4):. PubMed ID: 22340780
[TBL] [Abstract][Full Text] [Related]
10. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
11. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
14. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Farias AJ; Du XL
Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
[TBL] [Abstract][Full Text] [Related]
15. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
[TBL] [Abstract][Full Text] [Related]
16. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
18. Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer.
Gold HT; Shao H; Oratz R; Yu O; Hammer M; Richardson S; Boudreau D
Am J Clin Oncol; 2020 Feb; 43(2):101-106. PubMed ID: 31850918
[TBL] [Abstract][Full Text] [Related]
19. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
20. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
[Next] [New Search]